Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies.
about
A Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian CancerAnacardic acid enhances the proliferation of human ovarian cancer cellsmicroRNA 490-3P enhances the drug-resistance of human ovarian cancer cellsIdentification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancerFolate receptor-targeted multimodality imaging of ovarian cancer in a novel syngeneic mouse modelAn apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer.Follow-up of patients who are clinically disease-free after primary treatment for fallopian tube, primary peritoneal, or epithelial ovarian cancer: a Program in Evidence-Based Care guideline adaptation.Investigation of bendamustine HCL in a phase 2 study in women with resistant ovarian cancer.Investigation on tissue specific effects of pro-apoptotic micro RNAs revealed miR-147b as a potential biomarker in ovarian cancer prognosis.Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status.Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer.Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy.Prolonged survival after intraperitoneal interleukin-2 immunotherapy for recurrent ovarian cancer.LncRNA NEAT1 contributes to paclitaxel resistance of ovarian cancer cells by regulating ZEB1 expression via miR-194.Improvement in sexual function after ovarian cancer: Effects of sexual therapy and rehabilitation after treatment for ovarian cancer.3-Oxoacid CoA transferase 1 as a therapeutic target gene for cisplatin-resistant ovarian cancer.ADAM17 inhibition enhances platinum efficiency in ovarian cancer.MiR-744-5p inducing cell death by directly targeting HNRNPC and NFIX in ovarian cancer cells.
P2860
Q28551341-88F71BF2-4DA1-41DC-B110-5B11C19E4B02Q33748601-7BFC3BA4-3AA9-43F5-A675-75B307EDA3D2Q34150950-B331B006-5641-4688-99ED-FF424B08B762Q35044404-B9336665-E73B-4215-A8A6-FC00CF6F53F1Q35057527-AA331203-3251-4C97-B22B-B98478ED0FA6Q35941858-9B3E46DF-2B9C-4E2B-93E4-AD21FB91D3F9Q37367890-72B76CEE-808E-4F8D-9E54-048C4B44B3DAQ37705010-7B681281-EB9C-41AC-810E-FD5CF3E189BDQ37745830-F3CF04CD-DD4B-4649-9A25-BC0D63E68134Q38667138-D3968541-1E8F-47D0-880D-51F51163CE05Q40768444-F3F04062-49D5-4852-B680-5CA38BBB0F7DQ40996472-5FB2ECFE-EFE8-4557-B94D-0B0A29BF3C7EQ42373486-C1DE569C-DF75-46C2-AF0F-932C4AE380C0Q47163226-B9A4FD56-6D95-49AF-85FB-BF595D8A41B6Q47552154-D6363BAC-EB26-4653-AA70-C2C7A49C5CCDQ49777403-FD55B24E-8B1E-4098-87C1-357C77900778Q52584359-5932AC73-54B9-41B0-A4DC-619485FC6C68Q55364404-2BC33583-9C7C-4D18-B605-C60390F67402
P2860
Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Targeted treatment of recurren ...... urrent and emerging therapies.
@ast
Targeted treatment of recurren ...... urrent and emerging therapies.
@en
type
label
Targeted treatment of recurren ...... urrent and emerging therapies.
@ast
Targeted treatment of recurren ...... urrent and emerging therapies.
@en
prefLabel
Targeted treatment of recurren ...... urrent and emerging therapies.
@ast
Targeted treatment of recurren ...... urrent and emerging therapies.
@en
P2093
P2860
P356
P1476
Targeted treatment of recurren ...... urrent and emerging therapies.
@en
P2093
Anda M Vlad
Gina M Mantia-Smaldone
Robert P Edwards
P2860
P356
10.2147/CMR.S8759
P407
P577
2010-12-30T00:00:00Z